Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CONYSE:CORBFNASDAQ:MRAINASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOGlobal Cord Blood$1.45$1.11$2.03▼$5.50$176.25M0.16216,519 shsN/ACORBFGlobal Cord Blood$1.45$1.11$0.25▼$2.00$176.25M-0.52120,294 shsN/AMRAIMarpai$1.35-2.2%$1.27$0.40▼$1.68$22.32M4.7918,523 shs951 shsREPLReplimune Group$9.45-1.0%$9.04$6.44▼$17.00$736.18M0.61865,323 shs581,094 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOGlobal Cord Blood-3.33%-3.33%+45.00%+38.10%+45.00%CORBFGlobal Cord Blood0.00%-3.33%+45.00%+26.09%+45.00%MRAIMarpai-2.17%-6.90%-2.88%+40.63%+87.47%REPLReplimune Group-1.05%-0.11%-1.87%+26.68%+16.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/ACORBFGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/AMRAIMarpaiN/AN/AN/AN/AN/AN/AN/AN/AREPLReplimune Group4.0904 of 5 stars3.61.00.04.51.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOGlobal Cord Blood 0.00N/AN/AN/ACORBFGlobal Cord Blood 0.00N/AN/AN/AMRAIMarpai 0.00N/AN/AN/AREPLReplimune Group 3.13Buy$20.83120.46% UpsideCurrent Analyst Ratings BreakdownLatest CO, CORBF, MRAI, and REPL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.006/20/2025REPLReplimune GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight6/2/2025REPLReplimune GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOGlobal Cord Blood$1.24B0.14$0.35 per share4.19$6.34 per share0.23CORBFGlobal Cord Blood$196.12M0.90$1.04 per share1.40N/A∞MRAIMarpai$34.87M0.64N/AN/A($1.72) per share-0.78REPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOGlobal Cord Blood$79.04M$0.642.27∞N/AN/AN/AN/AN/ACORBFGlobal Cord Blood$79.04MN/A0.00∞N/AN/AN/AN/AN/AMRAIMarpai-$28.75M-$1.82N/A∞N/A-85.70%N/A-100.23%8/5/2025 (Estimated)REPLReplimune Group-$247.30M-$3.07N/AN/AN/AN/A-57.98%-45.21%8/6/2025 (Estimated)Latest CO, CORBF, MRAI, and REPL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q4 2025REPLReplimune Group-$0.75-$0.82-$0.07-$0.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOGlobal Cord Blood$0.085.52%N/A12.50%N/ACORBFGlobal Cord BloodN/AN/AN/AN/AN/AMRAIMarpaiN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOGlobal Cord BloodN/AN/AN/ACORBFGlobal Cord BloodN/AN/AN/AMRAIMarpaiN/A0.820.82REPLReplimune Group0.177.957.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOGlobal Cord BloodN/ACORBFGlobal Cord BloodN/AMRAIMarpai49.75%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipCOGlobal Cord Blood0.50%CORBFGlobal Cord Blood0.50%MRAIMarpai61.30%REPLReplimune Group8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOGlobal Cord Blood1,202121.55 millionN/ANo DataCORBFGlobal Cord Blood1,200121.55 millionN/ANot OptionableMRAIMarpai15016.53 million5.61 millionNo DataREPLReplimune Group21077.09 million70.30 millionOptionableCO, CORBF, MRAI, and REPL HeadlinesRecent News About These CompaniesHC Wainwright Reaffirms Buy Rating for Replimune Group (NASDAQ:REPL)3 hours ago | americanbankingnews.comReplimune Group (NASDAQ:REPL) Earns "Buy" Rating from HC WainwrightJuly 3 at 9:30 AM | marketbeat.comReplimune Group, Inc. (REPL) - Yahoo FinanceJuly 1 at 6:26 AM | finance.yahoo.comReplimune Group, Inc. (NASDAQ:REPL) Receives $20.83 Consensus Price Target from AnalystsJune 28, 2025 | americanbankingnews.comReplimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by AnalystsJune 25, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Replimune Group (REPL) with Overweight RecommendationJune 20, 2025 | msn.comReplimune Group (NASDAQ:REPL) Coverage Initiated at Cantor FitzgeraldJune 20, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Shares Sold by Bank of America Corp DEJune 14, 2025 | marketbeat.comReplimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 PlanJune 6, 2025 | quiverquant.comQReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comReplimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?June 4, 2025 | marketbeat.comReplimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingJune 1, 2025 | globenewswire.comReplimune to Present at the 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comReplimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA reviewMay 26, 2025 | investing.comEarnings call transcript: Replimune Q1 2025 sees stock drop post-earningsMay 24, 2025 | uk.investing.comREPLIMUNE GROUP Earnings Results: $REPL Reports Quarterly EarningsMay 24, 2025 | nasdaq.comReplimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call TranscriptMay 23, 2025 | insidermonkey.comEmily Luisa Hill Sells 2,535 Shares of Replimune Group, Inc. (NASDAQ:REPL) StockMay 23, 2025 | insidertrades.comQ4 2025 Replimune Group Inc Earnings CallMay 22, 2025 | uk.finance.yahoo.comReplimune Group, Inc. (REPL) Q4 2025 Earnings Call TranscriptMay 22, 2025 | seekingalpha.comReplimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate UpdateMay 22, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI Spending3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeCO, CORBF, MRAI, and REPL Company DescriptionsGlobal Cord Blood NYSE:CO$1.45 0.00 (0.00%) As of 07/2/2025Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.Global Cord Blood NYSE:CORBF$1.45 0.00 (0.00%) As of 07/2/2025Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.Marpai NASDAQ:MRAI$1.35 -0.03 (-2.17%) As of 07/3/2025 12:17 PM EasternMarpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services. Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida.Replimune Group NASDAQ:REPL$9.45 -0.10 (-1.05%) Closing price 07/3/2025 03:03 PM EasternExtended Trading$9.48 +0.03 (+0.26%) As of 07/3/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
